RNA Sequencing as Alternative to Immunohistochemistry in Cancer Diagnostics
By LabMedica International staff writers Posted on 06 Jul 2020 |
Image: The Bioanalyzer RNA 6000 Nano assay provides reliable and reproducible characterization of total RNA and mRNA from multiple sample types (Photo courtesy of Agilent Technologies).
The conventionally used method for cancer diagnostics relies on immunohistochemical dyeing of tumor tissue sections. It allows detecting the presence and measuring the concentration of marker proteins characterizing malignant growths. The resulting microscope images indicate whether the tumor is malignant and what its molecular type is. This information is crucial for selecting the right therapy.
Another alternative method is RNA sequencing which involves determining the sequence and the number of molecules for each RNA present in the cell. The resulting data, referred to as the transcriptome, reflects the activity of all genes in the cell. To analyze such vast arrays of data, bioinformaticians employ specialized algorithms and compile transcriptome databases for different human cells and tissues.
Scientists at the Moscow Institute of Physics and Technology (MIPT, Moscow, Russia) and their associates examined biosamples of tumor tissues that were formalin-fixed and embedded into paraffin blocks (FFPE). Tissue samples were obtained from 39 breast cancers (BC) and 19 lung cancer (LC). The team performed the first correlation study of RNA sequencing and immunohistochemistry-measured expression profiles for the clinically actionable biomarker genes in FFPE cancer tissue samples.
RNA was extracted from FFPE sections using a QIAGEN RNeasy FFPE Kit (Hilden, Germany). The RNA 6000 Nano (Agilent Technologies, San Clara, CA, USA) or Qubit RNA Assay kits (Thermo Fisher Scientific, Waltham, MA, USA) were used to measure RNA concentration. RNA Integrity Number (RIN) was measured using Agilent 2100 Bioanalyzer. Immunohistochemistry assay for BC samples for HER2, ESR1, and PGR proteins was performed using antibody kits (Roche Diagnostics, Indianapolis, IN, USA) to identify the respective statuses of the tumors. For HER2, the output statuses were confirmed using the Roche Diagnostic’s ISH DNA Probe Cocktail assay.
The team reported that they had demonstrated high and statistically significant correlations between the RNA sequencing (Oncobox protocol, OmicsWay Corp, Walnut, CA, USA) and immunohistochemical measurements for HER2/ERBB2, ER/ESR1 and PGR genes in BC, and for PDL1 gene in LC; AUC: 0.963 for HER2, 0.921 for ESR1, 0.912 for PGR, and 0.922 for PDL1.
Anton A. Buzdin, PhD, who heads the Laboratory for Translational Genomic Bioinformatics, said, “We have shown for the first time that the findings of both methods are in perfect agreement for the selected set of biomarkers. It's just that immunohistochemistry requires a much greater number of attempts, one for every biomarker considered, meaning that much more biomaterial is needed. In turn, RNA sequencing enables us to quantitatively characterize the work of all protein-encoding genes, and there are about 20,000 of them.” The study was originally published on May 9, 2020 in the journal Biomedicines.
Another alternative method is RNA sequencing which involves determining the sequence and the number of molecules for each RNA present in the cell. The resulting data, referred to as the transcriptome, reflects the activity of all genes in the cell. To analyze such vast arrays of data, bioinformaticians employ specialized algorithms and compile transcriptome databases for different human cells and tissues.
Scientists at the Moscow Institute of Physics and Technology (MIPT, Moscow, Russia) and their associates examined biosamples of tumor tissues that were formalin-fixed and embedded into paraffin blocks (FFPE). Tissue samples were obtained from 39 breast cancers (BC) and 19 lung cancer (LC). The team performed the first correlation study of RNA sequencing and immunohistochemistry-measured expression profiles for the clinically actionable biomarker genes in FFPE cancer tissue samples.
RNA was extracted from FFPE sections using a QIAGEN RNeasy FFPE Kit (Hilden, Germany). The RNA 6000 Nano (Agilent Technologies, San Clara, CA, USA) or Qubit RNA Assay kits (Thermo Fisher Scientific, Waltham, MA, USA) were used to measure RNA concentration. RNA Integrity Number (RIN) was measured using Agilent 2100 Bioanalyzer. Immunohistochemistry assay for BC samples for HER2, ESR1, and PGR proteins was performed using antibody kits (Roche Diagnostics, Indianapolis, IN, USA) to identify the respective statuses of the tumors. For HER2, the output statuses were confirmed using the Roche Diagnostic’s ISH DNA Probe Cocktail assay.
The team reported that they had demonstrated high and statistically significant correlations between the RNA sequencing (Oncobox protocol, OmicsWay Corp, Walnut, CA, USA) and immunohistochemical measurements for HER2/ERBB2, ER/ESR1 and PGR genes in BC, and for PDL1 gene in LC; AUC: 0.963 for HER2, 0.921 for ESR1, 0.912 for PGR, and 0.922 for PDL1.
Anton A. Buzdin, PhD, who heads the Laboratory for Translational Genomic Bioinformatics, said, “We have shown for the first time that the findings of both methods are in perfect agreement for the selected set of biomarkers. It's just that immunohistochemistry requires a much greater number of attempts, one for every biomarker considered, meaning that much more biomaterial is needed. In turn, RNA sequencing enables us to quantitatively characterize the work of all protein-encoding genes, and there are about 20,000 of them.” The study was originally published on May 9, 2020 in the journal Biomedicines.
Latest Molecular Diagnostics News
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access
- Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms
- Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis
- First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety
- Fluid Biomarker Test Detects Neurodegenerative Diseases Before Symptoms Appear